Eine Plattform für die Wissenschaft: Bauingenieurwesen, Architektur und Urbanistik
Eine Plattform für die Wissenschaft: Bauingenieurwesen, Architektur und Urbanistik
Bioorthogonal CRISPR/Cas9‐Drug Conjugate: A Combinatorial Nanomedicine Platform
Bioconjugation of proteins can substantially expand the opportunities in biopharmaceutical development, however, applications are limited for the gene editing machinery despite its tremendous therapeutic potential. Here, a self‐delivered nanomedicine platform based on bioorthogonal CRISPR/Cas9 conjugates, which can be armed with a chemotherapeutic drug for combinatorial therapy is introduced. It is demonstrated that multi‐functionalized Cas9 with a drug and polymer can form self‐condensed nanocomplexes, and induce significant gene editing upon delivery while avoiding the use of a conventional carrier formulation. It is shown that the nanomedicine platform can be applied for combinatorial therapy by incorporating the anti‐cancer drug olaparib and targeting the RAD52 gene, leading to significant anti‐tumor effects in BRCA‐mutant cancer. The current development provides a versatile nanomedicine platform for combination treatment of human diseases such as cancer.
Bioorthogonal CRISPR/Cas9‐Drug Conjugate: A Combinatorial Nanomedicine Platform
Bioconjugation of proteins can substantially expand the opportunities in biopharmaceutical development, however, applications are limited for the gene editing machinery despite its tremendous therapeutic potential. Here, a self‐delivered nanomedicine platform based on bioorthogonal CRISPR/Cas9 conjugates, which can be armed with a chemotherapeutic drug for combinatorial therapy is introduced. It is demonstrated that multi‐functionalized Cas9 with a drug and polymer can form self‐condensed nanocomplexes, and induce significant gene editing upon delivery while avoiding the use of a conventional carrier formulation. It is shown that the nanomedicine platform can be applied for combinatorial therapy by incorporating the anti‐cancer drug olaparib and targeting the RAD52 gene, leading to significant anti‐tumor effects in BRCA‐mutant cancer. The current development provides a versatile nanomedicine platform for combination treatment of human diseases such as cancer.
Bioorthogonal CRISPR/Cas9‐Drug Conjugate: A Combinatorial Nanomedicine Platform
Beha, Marcel Janis (Autor:in) / Kim, Joo‐Chan (Autor:in) / Im, San Hae (Autor:in) / Kim, Yunsu (Autor:in) / Yang, Seungju (Autor:in) / Lee, Juhee (Autor:in) / Nam, Yu Ri (Autor:in) / Lee, Haeshin (Autor:in) / Park, Hee‐Sung (Autor:in) / Chung, Hyun Jung (Autor:in)
Advanced Science ; 10
01.09.2023
14 pages
Aufsatz (Zeitschrift)
Elektronische Ressource
Englisch
Genome modification by CRISPR/Cas9
| British Library Online Contents | 2014
Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer
| Wiley | 2018
Efficient ssa‐mediated precise genome editing using crispr/cas9
| British Library Online Contents | 2018
Generation of eGFP and Cre knockin rats by CRISPR/Cas9
| British Library Online Contents | 2014
Progress and Perspective of CRISPR‐Cas9 Technology in Translational Medicine
| Wiley | 2023